Nasdaq

Gilead Presents New Findings on Profile of Descovy® for Potential Use as HIV Pre-exposure Prophylaxis Compared With Truvada®

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (NASDAQ: GILD) today presented additional results from the DISCOVER trial evaluating an investigational use of Descovy (emtricitabine 200 ...
Nasdaq

U.S. Food and Drug Administration Approves Descovy® for HIV Pre-Exposure Prophylaxis (PrEP)

- Descovy Demonstrated Non-inferior Efficacy and an Improved Bone and Renal Safety Profile Compared with Truvada® in People at Risk for Sexually Acquired HIV Infection in a Global Phase 3 Trial - ...
Financial Post

Gilead Canada Announces Notice of Compliance for DESCOVY® (emtricitabine, tenofovir alafenamide) for HIV Pre-Exposure Prophylaxis (PrEP)

— PrEP is part of the ongoing efforts by Gilead Canada to end the HIV epidemic — MISSISSAUGA, Ontario — Gilead Sciences Canada, Inc. (Gilead Canada) today announced that Health Canada has granted a ...
Slate

Your PrEP Is Not a Status Symbol

This post is part of Outward, Slate’s home for coverage of LGBTQ life, thought, and culture. Read more here. In October, the U.S. Food and Drug Administration approved the drug Descovy to be used as a ...
Monthly Prescribing Reference

FDA Approves Descovy for the Treatment of HIV-1

Gilead Sciences announced that the FDA has approved Descovy (emtricitabine/tenofovir alafenamide [F/TAF]) tablets for the treatment of HIV-1 infection. Gilead Sciences announced that the Food and Drug ...
FiercePharma

Gilead's converting Truvada PrEP users to Descovy faster than expected: analyst

In just two months since Descovy’s FDA PrEP approval, Gilead has converted about 10% of Truvada patients to the new drug, IQVIA weekly scripts suggest. (Gilead) () One big task for Gilead Sciences’ ...
Business Wire

Gilead Presents 96-week Discover Trial Data Supporting Non-inferior Efficacy and Key Safety Differences of Descovy For PrEP™ Compared With Truvada For PrEP ®

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) today announced 96-week results from the DISCOVER trial, a multi-year global Phase 3 registrational clinical trial evaluating ...
Monthly Prescribing Reference

Descovy for PrEP Continues to Be Noninferior to Truvada, According to 96 Week Data

Descovy demonstrated continued noninferiority to Truvada for HIV pre-exposure prophylaxis and statistically significant differences over Truvada for pre-specified secondary end points. In the phase 3, ...
NBC News

FDA approves Gilead's next-generation HIV PrEP pill, Descovy

Gilead Sciences, the drug giant behind the blockbuster HIV prevention pill Truvada, won FDA approval on Thursday to market Descovy — a medication already used by those who have HIV — as its ...
FiercePharma

Gilead's Descovy AdCom gets 'controversial' as panelists split over PrEP use in women

As expected, Gilead’s Descovy had no problem securing backing from an FDA panel of experts for HIV prevention in men and transgender women. But beyond that, it ran into some issues. On Wednesday, an ...
Business Wire

Gilead Canada Announces Notice of Compliance for DESCOVY® (emtricitabine, tenofovir alafenamide) for HIV Pre-Exposure Prophylaxis (PrEP)

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Gilead Sciences Canada, Inc. (Gilead Canada) today announced that Health Canada has granted a Notice of Compliance (NOC) for DESCOVY® (emtricitabine 200 mg and ...